Taiji Biopharmaceuticals Pvt. Ltd.

Overview

Taiji Biopharmaceuticals Pvt. Ltd. is a privately held company specializing in the development and commercialization of novel therapeutics. The company focuses on pioneering research in the field of biotechnology to address unmet medical needs worldwide.

Therapeutic areas

API / Drug Master Files

Taiji Biopharmaceuticals Pvt. Ltd. holds 157 active (157 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• OSILODROSTAT PHOSPHATEActive2026-03-31
• TROFINETIDEActive2026-03-01
• OLAPARIB PREMIXActive2026-03-01
• LOTILANERActive2025-12-31
• NIRAPARIB TOSYLATEActive2025-12-31
• LETERMOVIRActive2025-12-31
• MAVACAMTENActive2025-10-31
• MITAPIVAT SULFATEActive2025-10-31
• RESMETIROMActive2025-09-30
• ATALURENActive2025-09-30
• RIOCIGUATActive2025-07-31
• RUCAPARIB CAMSYLATEActive2025-07-31
• GADOXETATE DISODIUMActive2025-07-31
• EDOXABAN TOSYLATEActive2025-07-01
• MARALIXIBAT CHLORIDEActive2025-04-30

Showing 15 of 157 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Taiji Biopharmaceuticals Pvt. Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.